Numer badania | Tytuł badania | Nowotwór | Kategoria chorych | Faza badania | Sponsor badania | Data rozpoczęcia | Data zakończenia | Ośrodki badawcze | Sponsor badania | Linki |
---|---|---|---|---|---|---|---|---|---|---|
NCT00790036 | Phase III Study of RAD001 Adjuvant Therapy in Poor Risk... | DLBCL | III/IV stopień, CR po chemioterapii z rytuksymabem | III | Novartis | 2009-06-30 | 2014-04-30 |
Bydgoszcz; Łódź; Lublin; Warszawa
|
Novartis | |
NCT00822614 | Safety of Fentanyl TAIFUN Treatment | choroba nowotworowa | ból przebijający | III | Akela Pharma | 2008-11-30 | 2009-12-31 |
Zbigniew Kaczmarek - Włocławek
|
Akela Pharma | |
NCT00858364 | Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients... | n. rak płuca | po 1. linii | III | Amgen | 2009-08-31 | 2019-05-31 |
Bydgoszcz; Łomża; Olsztyn; Rzeszów; Suwałki; Szczecin; Warszawa; Wrocław
|
Amgen | |
NCT00883792 | The Northern-European Initiative on Colorectal Cancer | rak jelita | skrining | III | Norwegian Ministry of Health | 2009-04-30 | 2036-06-30 |
CO-I Warszawa - Jaroslaw Regula, MD PhD Ph: 48 606... |
Norwegian Ministry of Health | |
NCT00925600 | A Study to Evaluate New or Worsening Lens Opacifications in... | rak gruczołu krokowego | hormonooporny przerzutowy | III | Amgen | 2009-10-31 | 2014-01-31 |
Gdańsk; Gdynia; Katowice; Mysłowice; Opole; Poznań; Szczecin; Warszawa; Wrocław
|
Amgen | |
NCT00937183 | Phase I/II Study of Adjuvant Dendritic Cell-Lymphoma Cell Hybrids and/or... | chłoniak B-komórkowy | bez progresji | II | CO-I Warszawa | 2003-08-31 | 2010-05-31 |
CO-I Warszawa, Jan Walewski, MD Ph: 48-22-546-2223 walewski@coi.waw.pl
|
CO-I Warszawa | |
NCT01001377 | ASPECCT: A Study of Panitumumab Efficacy and Safety Compared to... | rak jelita grubego | przerzutowy/chemiooporny | III | Amgen | 2010-01-31 | 2013-07-31 |
Elbląg; Gdańsk; Jelenia Góra; Poznań; Szczecin; Warszawa
|
Amgen | |
NCT01004003 | Phase I/II Comparison of Efficacy and Safety of BIBF 1120... | rak wątroby | przerzutowy | II | Boehringer Ingelheim | 2009-09-30 | 2013-01-31 |
Warszawa
|
Boehringer Ingelheim | |
NCT01077154 | Study of Denosumab as Adjuvant Treatment for Women With High... | rak piersi | wczesny | III | Amgen | 2010-04-30 | 2021-09-30 |
Gdańsk; Kraków; Olsztyn; Poznań; Rzeszów; Szczecin
|
Amgen | |
NCT01077518 | Ofatumumab and Bendamustine Combination Therapy Compared With Bendamustine Monotherapy in... | chłoniak B-komórkowy | oporny na rituksymab | III | GSK | 2010-07-31 | 2022-04-30 |
Gdynia; Warszawa; Wrocław
|
GSK |